论文部分内容阅读
目的 观察宣白承气汤加减对痰热壅肺型重症肺炎的临床疗效。方法 将80例痰热壅肺型重症肺炎患者随机分为2组,对照组40例予重症肺炎标准治疗,治疗组40例在对照组基础上予宣白承气汤加减。治疗10 d后比较2组治疗前后动脉血乳酸含量、临床肺部感染评分(CPIS)及急性生理与慢性健康评分(A PA CH EⅡ),记录有创机械通气时间、ICU转出率,并统计疗效。结果 治疗组总有效率77.5%,优于对照组(52.5%,P<0.05)。治疗组治疗后动脉血乳酸含量、CPIS及A PA CH EⅡ评分较治疗前均明显下降(P<0.05),且改善情况均优于对照组(P<0.05)。对照组治疗后动脉血乳酸含量较治疗前下降(P<0.05)。治疗组有创机械通气时间低于对照组(P<0.05),ICU转出率高于对照组(P<0.05)。结论 宣白承气汤加减治疗痰热壅肺型重症肺炎疗效确切,且无不良反应。
Objective To observe the clinical efficacy of Xuanbai Chengqi Decoction on sputum pneumonia and severe pulmonary pneumonia. Methods Eighty cases of severe pneumonia with sputum pneumonia and severe pneumonia were randomly divided into two groups. 40 cases in the control group were given standard treatment of severe pneumonia, and 40 cases in the treatment group were treated with Xuanbai Chengqi Decoction on the basis of the control group. After 10 days of treatment, the arterial blood lactic acid content, clinical lung infection score (CPIS) and acute physiology and chronic health score (A PA CH E II) were compared between the two groups before and after treatment. The time of mechanical ventilation, the rate of ICU transfer and statistics Efficacy. Results The total effective rate was 77.5% in the treatment group, which was better than that in the control group (52.5%, P <0.05). After treatment, the arterial blood lactic acid content, CPIS and A PA CH EⅡ scores in treatment group were significantly lower than those before treatment (P <0.05), and the improvement was better than that in control group (P <0.05). The arterial blood lactic acid content of the control group decreased after treatment (P <0.05). The duration of invasive mechanical ventilation in the treatment group was lower than that of the control group (P <0.05), and the rate of ICU outflow was higher than that of the control group (P <0.05). Conclusion Xuanbai Chengqi Decoction is effective in treating severe pneumonitis with phlegm-heat syndrome and has no adverse reactions.